Cardiorenal syndrome - A new classification and current evidence on its management

Clinical Nephrology

Volumn 74, Issue 4, 2010, Pages 245-257

  Ahmed, M S ^a   Wong, C F ^b   Pai, P ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Cardiorenal syndrome; Heart failure; Renal failure; Ultrafiltration; blockers

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; ETANERCEPT; FUROSEMIDE; LOOP DIURETIC AGENT; NESIRITIDE; NEUROHORMONE; RECOMBINANT BRAIN DERIVED NEUROTROPHIC FACTOR; ROLOFYLLINE; SPIRONOLACTONE; TEZOSENTAN; TOLVAPTAN; VASOPRESSIN ANTAGONIST;

ADRENERGIC SYSTEM; CARDIORENAL SYNDROME; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; HYPONATREMIA; KIDNEY DYSFUNCTION; MORALITY; MORBIDITY; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SUDDEN DEATH; TREATMENT INDICATION; ULTRAFILTRATION;

EID: 77957671889     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp74245     Document Type: Review

References (61)

1. Cowie MR, Mosterd A, Wood DA et al. The epidemiology of heart failure. Eur Heart J. 1997; 18: 208-225.
2. McCullough PA, Sandberg KR, Borzak S. Cardiovascular outcomes and renal disease. Ann Intern Med. 2002; 136: 633-634.
3. Cheung AK, Sarnak MJ, Yan Get al. HEMO Study Group. Cardiac diseases in maintenancehemodialysis patients: results of the HEMO Study. Kidney Int. 2004; 65: 2380-2389.
4. Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004; 43: 61-67. (Pubitemid 38045917)
5. Smith GL, Lichtman JH, Bracken MB et al. Renal impairment and outcomes in heart failure. Systematic review and meta-analysis. J Am Coll Cardiol. 2006; 47: 1987-1996.
6. Damman K, Jaarsma T, Voors AA et al. Both inand out-hospital worsening of renal function predict outcome in patients heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). Eur J Heart Fail. 2009; 11: 847-854.
7. Ronco C, Haapio M, House AA et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008; 52: 1527-1539.
8. Cadnapaphornchai MA, Gurevich AK, Weinberger HD et al. Pathophysiology of sodium and water retention in heart failure. Cardiology. 2001; 96: 122-131. (Pubitemid 34114122)
9. Jong P, Vowinckel E, Liu PP et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med. 2002; 162: 1689-1694.
10. Ferrari R, Bachetti T, Confortini R et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 1995; 92: 1479-1486.
11. Kalra DK, Zhu X, Ramchandani MK et al. Increased myocardial gene expression of tumor necrosis factor-alpha and nitric oxide synthase-2: a potential mechanism for depressed myocardial function in hibernating myocardium in humans. Circulation. 2002; 105: 1537-1540.
12. Sakurai S, Adachi H, Hasegawa A et al. Brain natriuretic peptide facilitates severity classification of stable chronic heart failure with left ventricular dysfunction. Heart. 2003; 89: 661-662.
13. Tang WH, Mullens W. Cardio-Renal Syndrome in Decompensated Heart Failure. Heart. 2010; 96: 255-260.
14. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001; 96: 132-143. (Pubitemid 34114123)
15. Dahle TG, Sobotka PA, Boyle AJ. Apractical guide for ultrafiltration in acute decompensated heart failure. Congest Heart Fail. 2008; 14: 83-88.
16. Rogers HL, Marshall J, Bock J et al. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail. 2008; 14: 1-5.
17. Costanzo MR, Guglin ME, Saltzberg MT et al. UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007; 49: 684-686.
18. Bart BA, Boyle A, Bank AJ et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients with Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol. 2005; 46: 2052-2053.
19. Ronco C, Ricci Z, Bellomo R et al. Extracorporeal ultrafiltration for the treatment of over hydration and congestive heart failure. Cardiology. 2001; 96: 155-168. (Pubitemid 34114125)
20. Mehorta R. Peritoneal dialysis in adult patients without end stage renal disease. Adv Perit Dial. 2000; 16: 67-71.
21. König PS, Lhotta K, Kronenberg F et al. A successful treatment in patients suffering from therapy resistant congestive heart failure. Adv Perit Dial. 1991; 7: 97-101.
22. Yancy CW, Krum H, Massie BM et al. FUSION II Investigators. The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. Am Heart J. 2007; 153: 478-484.
23. McMurray JJ, Teerlink JR, Cotter G et al. VERITAS Investigators. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITASrandomized controlled trials. JAMA. 2007; 298: 2009-2019.
24. Konstam MA, Gheorghiade M, Burnett JC Jr et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007; 297: 1319-1331.
25. Givertz MM, Massie BM, Fields TK et al. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol. 2007; 50: 1551-1560.
26. Mann DL, McMurray JJ, Packer M et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004; 109: 1594-1602.
27. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005; 111: 1487-1491.
28. McMurray JJ, Ray SG, Abdullah I et al. Plasma endothelin in chronic heart failure. Circulation. 1992; 85: 1374-1379.
29. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005; 46: 1785-1791.
30. Vallon V, Muhlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev. 2006; 86: 901-940.
31. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med. 2003; 138: 917-924.
32. Tokmakova MP, Skali H, Kenchaiah S et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival and Ventricular Enlargement (SAVE) study. Circulation. 2004; 110: 3667-3673. (Pubitemid 39665255)
33. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709-717.
34. Weir RA, McMurray JJ, Puu M et al. CHARM Investigators. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Eur J Heart Fail. 2008; 10: 157-163.
35. JN Cohn, G Tognoni. Valsartan Heart Failure Trial Investigators A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure. N Engl J Med. 2001; 345: 1667-1675.
36. Herzog CA. Don't forget the defibrillator in the dialysis unit. Nephrol Dial Transplant. 2004; 19: 2959-2960.
37. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet. 2001; 357: 1385-1390. (Pubitemid 32455364)
38. Packer M, Fowler MB, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002; 106: 2194-2199.
39. Cice G, Ferrara L, D'Andrea A et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003; 41: 1438-1444.
40. Abbott KC, Trespalacios FC, Agodoa LY et al. Beta-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med. 2004; 164: 2465-2471. (Pubitemid 39628074)
41. Reiter MJ. Cardiovascular drug class specificity: beta-blockers. Prog Cardiovasc Dis. 2004; 47: 11-33.
42. Freemantle N, Cleland J, Young P et al. Beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999; 318: 1730-1737. (Pubitemid 29290470)
43. Ablad B, Bjurö T, Björkman JA et al. Prevention of ventricular fibrillation requires central beta adrenoceptor blockade in rabbits. Scand Cardiovasc J. 2007; 41: 221-229.
44. Bakris GL, Hart P, Ritz E. Beta-blockers in the management of chronic kidney disease. Kidney Int. 2006; 70: 1905-1913.
45. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int. 1997; 51: 722-727.
46. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J am Soc Nephrol. 2004; 15: 524-537.
47. Packer M. Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med. 2001; 110: 81-94.
48. Amann K, Rump LC, Simonaviciene A et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol. 2000; 11: 1469-1478. (Pubitemid 30483463)
49. Hampl H, Sternberg C, Berweck S et al. Regression of left ventricular hypertrophy in hemodialysis patients is possible. Clin Nephrol. 2002; 58 (Suppl): 73-96. (Pubitemid 35221544)
50. Palazzuoli A, Silverberg DS, Iovine F et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J. 2007; 154: 645.e9-15.
51. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanivich P, Kewlramani R, Levey AS, Lewis EF. A trial of darbepoietin alfa in typ 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361: 2019-2032.
52. Singh AK, Szczech L, Tang KL et al. CHOIR investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098. (Pubitemid 44749317)
53. Drüeke TB, Locatelli F, Clyne N et al. CREATE investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355: 2071-2084.
54. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339: 584-590.
55. Fishbane S. Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective. Kidney Int. 2009; 75: 358-365.
56. Hampl H, Riedel E. Cardiac disease in the dialysis patient: good, better, best clinical practice. Blood Purif. 2009; 27: 99-113.
57. Streja E, Kovesdy CP, Greenland S et al. Erythropoietin, iron depletion, and reactive thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis. 2009; 52: 727-736.
58. Tekin D, Yavuzer S, Tekin M, Akar N, Cin S. Possible effects of antioxidant status on increased platelet aggregation in childhood iron-deficiency anemia. Pediatr Int. 2001; 43: 74-77. (Pubitemid 32171252)
59. Kalendar-Zadeh K, Regidor DL, McAllister CJ et al. Time-dependent associations between iron and mortality in hemodialysis patients J Am Soc Nephrol. 2005; 16: 3070-3080.
60. Culleton BF, Manns BJ, Zhang J et al. Impact of anemia on hospitalization and mortality in older adults. Blood. 2006; 107: 3841-3846. (Pubitemid 43726785)
61. Kovesdy CP, Estrada W, Ahmadzadeh S et al. Association of markers with outcomes in patients with nondialysis-dependent chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4: 435-441.